Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc.
P.O. Box 134
Malvern, PA 19355
United States
610 725 1500
https://www.galeratx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. J. Mel Sorensen M.D. | CEO, President & Director | 632.64k | N/D | 1957 |
| Dr. Robert A. Beardsley M.B.A., Ph.D. | Co-Founder & COO | 464.59k | N/D | 1962 |
| Mr. Christopher Degnan | Chief Financial Officer | 474.05k | N/D | 1980 |
| Ms. Jennifer Evans Stacey Esq. | Chief Legal & Compliance Officer and Secretary | N/D | N/D | 1965 |
| Ms. Andie Collier | Chief Regulatory & Quality Affairs Officer | N/D | N/D | N/D |
| Ms. Judy Schnyder | Senior Vice President of Clinical Operations & Data Management | N/D | N/D | N/D |
Descripción
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Galera Therapeutics, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 7; Compensación: 8.
